Skip to Content

Hydralazine injection

Last Updated: August 1, 2018
Status: Current

Products Affected - Description
    • Hydralazine injection, Akorn, 20 mg/mL, 1 mL vial, 25 count, NDC 17478-0934-15
    • Hydralazine injection, American Regent, 20 mg/mL, 1 mL vial, 25 count, NDC 00517-0901-25
    • Hydralazine injection, Fresenius Kabi, 20 mg/mL, 1 mL vial, 25 count, NDC 63323-0614-01
    • Hydralazine injection, X-Gen, 20 mg/mL, 1 mL vial, 25 count, NDC 39822-0500-04
Reason for the Shortage
    • Akorn has product on back order due to increased demand.
    • American Regent did not provide a reason for the shortage.
    • Fresenius Kabi did not provide a reason for the shortage.
    • X-Gen did not provide a reason for the shortage.
Available Products
    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Akorn has hydralazine 20 mg/mL 1 mL vials on back order and the company cannot estimate a release date.
    • American Regent has hydralazine 20 mg/mL 1 mL vials on back order and the company cannot estimate a release date.
    • Fresenius Kabi has hydralazine 20 mg/mL 1 mL vials on back order and the company estimates a release date of early-August 2018.
    • X-Gen has hydralazine 20 mg/mL 1 mL vials on back order and the company estimates a release date of mid-August 2018.

Updated

Updated August 1, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 4, 2018 by Anthony Trovato, Pharmacy Resident. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide